ENVIONEER Co.,Ltd. (KOSDAQ:317870)
South Korea · Delayed Price · Currency is KRW 14,890
+490 (3.40%)
At close: Aug 5, 2025, 3:30 PM KST
Ligand Pharmaceuticals Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 12,791 | 14,224 | 14,655 | 11,024 | 8,871 | 8,190 |
Other Revenue | -0 | -0 | - | - | - | - |
| 12,791 | 14,224 | 14,655 | 11,024 | 8,871 | 8,190 | |
Revenue Growth (YoY) | -23.56% | -2.94% | 32.94% | 24.27% | 8.31% | - |
Cost of Revenue | 11,080 | 11,044 | 10,182 | 7,279 | 6,200 | 5,896 |
Gross Profit | 1,711 | 3,180 | 4,473 | 3,745 | 2,671 | 2,295 |
Selling, General & Admin | 3,206 | 3,186 | 2,620 | 2,507 | 1,571 | 1,606 |
Research & Development | 1,919 | 1,792 | 1,798 | 1,718 | 1,632 | 1,511 |
Other Operating Expenses | 59.66 | 63.22 | 38.68 | 21.28 | 15.63 | 0.8 |
Operating Expenses | 5,424 | 5,302 | 4,685 | 4,447 | 3,438 | 3,284 |
Operating Income | -3,713 | -2,122 | -212.6 | -701.34 | -766.89 | -989.2 |
Interest Expense | -288.24 | -288.24 | -432.3 | -876.61 | -714.78 | -124.41 |
Interest & Investment Income | 303.54 | 303.54 | 378.38 | 199.37 | 104.17 | 100.59 |
Currency Exchange Gain (Loss) | 145.44 | 145.44 | -0.06 | -39.37 | -16.12 | 0.33 |
Other Non Operating Income (Expenses) | -36.33 | -72.77 | -3,598 | 1,308 | -529.01 | 21.26 |
EBT Excluding Unusual Items | -3,589 | -2,034 | -3,865 | -109.61 | -1,923 | -991.43 |
Gain (Loss) on Sale of Investments | -33.54 | -33.71 | -3.52 | 127.86 | -199.5 | 79.46 |
Gain (Loss) on Sale of Assets | -266.53 | -266.53 | -37.15 | - | 5.62 | 36.99 |
Asset Writedown | - | - | - | - | -277.14 | -10.67 |
Other Unusual Items | 194.2 | 194.2 | - | - | - | - |
Pretax Income | -3,694 | -2,140 | -3,905 | 18.25 | -2,394 | -885.65 |
Income Tax Expense | -23.94 | -23.94 | 26.9 | -55.27 | -29.49 | 1,063 |
Earnings From Continuing Operations | -3,671 | -2,116 | -3,932 | 73.51 | -2,364 | -1,949 |
Minority Interest in Earnings | 1,124 | 410.79 | -732.82 | -236.53 | -44.08 | - |
Net Income | -2,546 | -1,705 | -4,665 | -163.01 | -2,408 | -1,949 |
Net Income to Common | -2,546 | -1,705 | -4,665 | -163.01 | -2,408 | -1,949 |
Shares Outstanding (Basic) | 8 | 9 | 8 | 8 | 8 | 7 |
Shares Outstanding (Diluted) | 8 | 9 | 8 | 9 | 8 | 7 |
Shares Change (YoY) | 1.47% | 4.07% | -7.82% | 15.77% | 2.17% | - |
EPS (Basic) | -300.29 | -200.45 | -570.77 | -20.89 | -314.43 | -259.98 |
EPS (Diluted) | -300.29 | -200.45 | -571.00 | -62.40 | -314.43 | -260.00 |
Free Cash Flow | -15,684 | -14,895 | -16,799 | 612.93 | -3,710 | -1,989 |
Free Cash Flow Per Share | -1849.68 | -1751.11 | -2055.33 | 69.13 | -484.39 | -265.28 |
Gross Margin | 13.38% | 22.36% | 30.52% | 33.97% | 30.11% | 28.02% |
Operating Margin | -29.03% | -14.92% | -1.45% | -6.36% | -8.64% | -12.08% |
Profit Margin | -19.91% | -11.99% | -31.83% | -1.48% | -27.15% | -23.79% |
Free Cash Flow Margin | -122.62% | -104.71% | -114.63% | 5.56% | -41.82% | -24.28% |
EBITDA | -1,825 | -374.46 | 1,212 | 660.49 | 643.47 | 102.74 |
EBITDA Margin | -14.27% | -2.63% | 8.27% | 5.99% | 7.25% | 1.25% |
D&A For EBITDA | 1,888 | 1,747 | 1,425 | 1,362 | 1,410 | 1,092 |
EBIT | -3,713 | -2,122 | -212.6 | -701.34 | -766.89 | -989.2 |
EBIT Margin | -29.03% | -14.92% | -1.45% | -6.36% | -8.64% | -12.08% |
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.